Compare OOMA & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | PRTA |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 449.7M |
| IPO Year | 2015 | 2013 |
| Metric | OOMA | PRTA |
|---|---|---|
| Price | $20.56 | $9.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $18.77 | ★ $19.00 |
| AVG Volume (30 Days) | 357.3K | ★ 421.9K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | N/A |
| EPS | 0.09 | ★ 0.26 |
| Revenue | ★ $114,490,000.00 | $814,000.00 |
| Revenue This Year | $20.35 | $1,111.38 |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $228.78 | ★ $36.23 |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $7.73 |
| 52 Week High | $22.72 | $11.80 |
| Indicator | OOMA | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 54.92 |
| Support Level | $19.49 | $8.83 |
| Resistance Level | $21.57 | $9.36 |
| Average True Range (ATR) | 0.92 | 0.41 |
| MACD | -0.13 | 0.07 |
| Stochastic Oscillator | 14.41 | 67.98 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.